Vesence | $9,000,000 | (Oct 30, 2025)
Sparrow BioAcoustics | $10,000,000 | (Oct 30, 2025)
Reflectiz | $22,000,000 | (Oct 30, 2025)
Evozyne
United States
- Chicago, IL
- 28/09/2023
- Series B
- $81,000,000
Evozyne combines evolution and deep learning technology to create highly functional novel proteins — Natural Machines™ — to solve longstanding challenges in therapeutics and sustainability. By amplifying a protein’s function based on the rules of nature, we address complex, high-impact problems. From developing life-changing patient treatments to making carbon capture a reality, Evozyne is committed to making a healthier, more sustainable world.
- Industry Biotechnology
- Website https://www.evozyne.com/
- LinkedIn https://www.linkedin.com/company/evozyne/about/
Related People
Mike GamsonFounder
United States -
Greater Chicago Area
I'm passionate about leading teams to pursue inspiring goals. I love working with intellectually curious people who can do anything, but show up everyday with humility and a drive to be better than they were yesterday. I believe that driving results matters as does taking the time in life to stop to smell the roses. I aspire to be a great colleague and I hope to be a student of new things forever.
Mem0 | $24,000,000 | (Oct 30, 2025)
Valthos | $30,000,000 | (Oct 30, 2025)
Mondra | $13,206,500 | (Oct 30, 2025)
hoop.dev | Undisclosed Amount | (Oct 30, 2025)
IORGANBIO | $2,000,000 | (Oct 30, 2025)
FrontlineIQ | $3,300,000 | (Oct 30, 2025)
Homecourt | $8,000,000 | (Oct 30, 2025)
VentureMed Inc. | $28,000,000 | (Oct 30, 2025)
Recess | $30,000,000 | (Oct 30, 2025)